Development

Novocure's glioblastoma expansion bid fails, leaving Optune's label unchanged

A Phase III trial failure that leaves Novocure's approved label intact but closes the door on a meaningful expansion opportunity — that is the central...

Edited by Robert McTiernan··3 min read
Novocure's glioblastoma expansion bid fails, leaving Optune's label unchanged

Novocure (Nasdaq: NVCR) announced that its Phase III TRIDENT trial in newly diagnosed glioblastoma failed to meet its primary endpoint of overall survival, showing no statistically significant benefit from initiating Tumor Treating Fields (TTFields) therapy during chemoradiation compared with the current approach of starting treatment after completion of chemoradiation.

The study enrolled 981 patients shortly after surgery and randomized them to begin TTFields either concurrently with chemoradiation or at the start of maintenance therapy. Patients in both arms continued TTFields alongside maintenance temozolomide. In the intent-to-treat population, the trial reported a hazard ratio of 0.953 and a p-value of 0.519 for overall survival.

The result leaves Novocure's approved Optune Gio franchise unchanged. TTFields remains approved for use in combination with maintenance temozolomide in newly diagnosed glioblastoma based on the Phase III EF-14 trial, which supported FDA approval in 2015. TRIDENT was designed to determine whether moving TTFields earlier in the treatment course could further improve outcomes.

Median overall survival was 17.7 months in the Early Start arm and 17.5 months in the Maintenance Start arm. Three-year survival rates were 22.5% and 18.4%, respectively. While survival outcomes in both groups compare favorably with historical benchmarks in glioblastoma, the trial did not demonstrate a meaningful difference between treatment strategies.

The study population reflected routine clinical practice, with a median age of 60 years, 39% of patients carrying a methylated MGMT promoter, and 51% undergoing gross total resection. Approximately one-quarter of patients in both arms did not reach the maintenance phase, underscoring the challenges associated with treating newly diagnosed glioblastoma.

Novocure reported no new safety signals, and concurrent administration of TTFields with chemoradiation was found to be feasible. The company said additional analyses will be presented at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting, including subgroup assessments that may help identify patient populations more likely to benefit from earlier initiation.

The AllSci BriefSystematic R&D and deal news. Daily.

The newly diagnosed glioblastoma treatment landscape remains one of the most challenging areas in oncology. The standard-of-care regimen of surgery followed by radiation and temozolomide, then maintenance temozolomide with Optune Gio, has remained largely unchanged for years. While several investigational approaches are generating encouraging early-stage data, few have demonstrated benefits in large randomized studies.

Among emerging competitors, IN8bio recently reported updated Phase I/II results for its DeltEx DRI gamma-delta T-cell therapy, while Sapience Therapeutics presented Phase II data for lucicebtide in newly diagnosed glioblastoma. However, both programs remain at earlier stages of development and are based on substantially smaller datasets than TRIDENT.

For Novocure, the outcome narrows the near-term development path for TTFields in glioblastoma. The company continues to market Optune Gio in newly diagnosed disease and recently expanded the TTFields platform into pancreatic cancer with the approval of Optune Pax following the positive Phase III PANOVA-3 trial.

The full TRIDENT dataset will be presented at ASTRO 2026. While subgroup analyses may generate hypotheses for future studies, the topline results indicate that initiating TTFields during chemoradiation does not improve survival compared with starting treatment during the maintenance phase in an unselected population of patients with newly diagnosed glioblastoma.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article